Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00906204 · ClinicalTrials.gov registry record · Phase 2
Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation
A Phase 2 study of End Stage Renal Disease and Kidney Failure, sponsored by Wright State University.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 4
- Study locations
NCT00906204 is a Phase 2 study of End Stage Renal Disease and Kidney Failure that has completed, run by Wright State University. The registered enrollment target is 99 participants, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (88% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT00906204, a Phase 2 study of End Stage Renal Disease and Kidney Failure, has completed, sponsored by Wright State University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 4
- Study locations
Study Summary
In a non-blinded pilot study conducted at the University of Nebraska Medical Center, evidence was found that a single large dose of Thymoglobulin on the day of kidney transplantation produced better kidney function than the standard dosing plan, when the same amount is divided into smaller doses on 4 days. This new study repeats that dose comparison, but with double-blinding and at multiple transplantation centers.
Conditions Studied
Interventions
- BIOLOGICAL Single-dose rabbit Anti-thymocyte Globulin induction
- BIOLOGICAL Divided-dose rabbit Anti-thymocyte Globulin induction
Study Locations (4)
Arizona
- University of Arizona - Tucson
Nebraska
- University of Nebraska Medical Center - Omaha
North Carolina
- Wake Forest University - Winston-Salem
Texas
- The Methodist Hospital Research Institute - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2010-03 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00906204
The ClinicalTrials.gov registry entry for NCT00906204 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (88% lower). The listed sponsor is Wright State University, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 2 interventions - of which Single-dose rabbit Anti-thymocyte Globulin induction is the first listed.
NCT00906204 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Nebraska, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00906204 about?
NCT00906204 is a clinical study titled "Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation". In a non-blinded pilot study conducted at the University of Nebraska Medical Center, evidence was found that a single large dose of Thymoglobulin on the day of kidney transplantation produced better kidney function than the standard dosing plan, when the same amount is divided into smaller doses on ...
What is the current status of trial NCT00906204?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2010-03. Estimated completion is 2014-07.
What conditions does trial NCT00906204 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Kidney Failure.
What interventions are being tested in trial NCT00906204?
The interventions under investigation include: Single-dose rabbit Anti-thymocyte Globulin induction (BIOLOGICAL), Divided-dose rabbit Anti-thymocyte Globulin induction (BIOLOGICAL).
Who is sponsoring clinical trial NCT00906204?
This trial is sponsored by Wright State University, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00906204 being conducted?
This trial has 4 study locations across Arizona, Nebraska, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
RECRUITING · Phase 2
-
Safety and Efficacy of Empagliflozin in Hemodialysis
RECRUITING · Phase 2
-
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
RECRUITING · Phase 2
-
Communication During Hospitalization About Resuscitation Trial
ACTIVE NOT RECRUITING · Phase 2
-
The Effects of Resistance Exercise and Protein Supplementation in Hemodialysis Patients
COMPLETED · Phase 2
-
Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.